Nachrichten zur Argenx SE (ADRs) Aktie

Is Argenx Stock a Buy Now?

Good news keeps rolling in for the biotech....…

Argenx SE GAAP EPS of -$1.69 misses by $0.11, revenue of $281.04M beats by $28.21M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

July 27, 2023...…

Argenx SE Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx announces closing of global offering

Regulated information – Inside information...…

Why Shares of Argenx Jumped This Week

The companys lead therapy showed progress in treating an autoimmune disorder....…

argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023

July 20, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives…

Argenx prices global offering to raise $1.1B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx raises $1.1 billion in gross proceeds in a global offering

Regulated information — Inside information...…

ADRs End Higher, Foresight Autonomous and Argenx Trade Actively

ADRs End Higher, Foresight Autonomous and Argenx Trade Actively...…

Argenx Launches $750M Global Offering

Argenx Launches $750M Global Offering...…

Argenx plans for $750M global offering

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx announces launch of proposed global offering

Regulated information — Inside information...…

Immunovant stock jumps on positive data for Argenx drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Argenx Stock Is on Fire Today

A major clinical win is boosting the drugmakers shares today....…

Argenx/Zai Lab rise on phase 2 results for autoimmune disorder asset

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results

Argenx Shares Hit 52-Week High After Positive Vyvgart Hytrulo Trial Results...…

Argenx drug boost is mixed blessing for suitors

...LONDON (Reuters Breakingviews) - Argenx has long been a presumed......…

Form 6-K ARGENX SE For: Jul 17

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo

Argenx, Zai Lab Shares Rise After Positive Trial Results for Vyvgart Hytrulo...…

Biggest stock movers today: BridgeBio Pharma, Zai Lab, argenx and more

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

SHANGHAI, China and CAMBRIDGE, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688)…

argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Regulated information – Inside information...…

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

Amsterdam, the Netherlands— June 30, 2023 -- argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX:…

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

First-and-only approved FcRn antagonist for gMG patients by NMPA...…

Form 6-K ARGENX SE For: Jun 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx wins FDA nod for myasthenia gravis therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx Says FDA Approves Vyvgart Hytrulo Injection to Treat Neuromuscular Disease gMG

Argenx Says FDA Approves Vyvgart Hytrulo Injection to Treat Neuromuscular Disease gMG...…

argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis

Regulated Information/Inside Information...…

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Regulated Information/Inside Information...…

The Latest Analyst Ratings for argenx

Latest Ratings for ARGX DateFirmActionFromTo Mar 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Morgan StanleyMaintainsEqual-Weight Jan 2022Morgan StanleyMaintainsEqual-Weight View…

UBS starts Argenx at buy, sees drug Vyvgart as potential "megabuster"

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx to Present at Upcoming Investor Conferences

May 31, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives…

Argenx, Blueprint Medicines, Sarepta likely M&A targets - analyst

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx gains amid report of takeover interest from drugmakers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K ARGENX SE For: May 05

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Argenx SE GAAP EPS of -$0.52 beats by $1.72, revenue of $219.14M beats by $18.6M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

argenx Reports First Quarter 2023 Financial Results and Provides Business Update

Regulated Information/Inside InformationMay 4, 2023...…

argenx to Present at BofA Securities 2023 Health Care Conference

May 2, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives…

argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023

April 27, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives…

argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting

Amsterdam, the Netherlands – [04/18/2023] argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives…

dpa-AFX ProFeed